Fc?RIIb expression in early stage chronic lymphocytic leukemia


Por: Bosch R., Mora A., Vicente E.P., Ferrer G., Jansà S., Damle R., Gorlatov S., Rai K., Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C.

Publicada: 1 ene 2017
Resumen:
In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor Fc?RIIb (CD32b). To better understand the role of Fc?RIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. Fc?RIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. Fc?RIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low Fc?RIIb expression (69/155, 44.5%) required therapy earlier than those with high Fc?RIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of Fc?RIIb in CLL biology and prognostic significance in larger series of patients. © 2017 Informa UK Limited, trading as Taylor & Francis Group.

Filiaciones:
Bosch R.:
 Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain

 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Mora A.:
 Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain

 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Vicente E.P.:
 Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain

 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Ferrer G.:
 Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, United States

Jansà S.:
 Department of Human Anatomy and Embryology, University of Barcelona, Barcelona, Spain

Damle R.:
 Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, United States

Gorlatov S.:
 MacroGenics, Inc, Rockville, MD, United States

Rai K.:
 Haematology/Oncology, Oncology LIJ Medical Centre, Lake Success, NY, United States

Montserrat E.:
 Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, Barcelona, Spain

Nomdedeu J.:
 Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Pratcorona M.:
 Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Blanco L.:
 Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Saavedra S.:
 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Garrido A.:
 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Esquirol A.:
 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Garcia I.:
 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Granell M.:
 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Martino R.:
 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Delgado J.:
 Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, Barcelona, Spain

Sierra J.:
 Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain

 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Chiorazzi N.:
 Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, United States

Moreno C.:
 Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain

 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
ISSN: 10428194
Editorial
TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 58 Número: 11
Páginas: 2642-2648
WOS Id: 000406274600017
ID de PubMed: 28372509
imagen

MÉTRICAS